NanoVibronix Inc (NAOV) - Total Liabilities
Based on the latest financial reports, NanoVibronix Inc (NAOV) has total liabilities worth $11.92 Million USD as of September 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Also explore net asset momentum of NanoVibronix Inc to track the company's year-over-year net asset growth rate.
NanoVibronix Inc - Total Liabilities Trend (2011–2024)
This chart illustrates how NanoVibronix Inc's total liabilities have evolved over time, based on quarterly financial data. See free cash flow generation of NanoVibronix Inc to measure how efficiently the company converts operating cash flow to free cash.
NanoVibronix Inc Competitors by Total Liabilities
The table below lists competitors of NanoVibronix Inc ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Blockmate Ventures Inc
V:MATE
|
Canada | CA$7.26 Million |
|
Aino Health AB
ST:AINO
|
Sweden | Skr9.57 Million |
|
Innity Corporation Bhd
KLSE:0147
|
Malaysia | RM39.63 Million |
|
CPPGroup Plc
F:4CV1
|
Germany | €22.06 Million |
|
Moho Resources Ltd
AU:MOH
|
Australia | AU$128.39K |
|
Mittal Life Style Limited
NSE:MITTAL
|
India | Rs253.54 Million |
|
Chrysalis Investments Ltd
LSE:CHRY
|
UK | GBX72.41 Million |
Liability Composition Analysis (2011–2024)
This chart breaks down NanoVibronix Inc's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the full company profile including market capitalisation, see NanoVibronix Inc (NAOV) total market value.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 0.86 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.28 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.22 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how NanoVibronix Inc's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for NanoVibronix Inc (2011–2024)
The table below shows the annual total liabilities of NanoVibronix Inc from 2011 to 2024.
| Year | Total Liabilities | Change |
|---|---|---|
| 2024-12-31 | $3.00 Million | +11.76% |
| 2023-12-31 | $2.69 Million | +1.51% |
| 2022-12-31 | $2.65 Million | +14.60% |
| 2021-12-31 | $2.31 Million | -60.43% |
| 2020-12-31 | $5.83 Million | +748.11% |
| 2019-12-31 | $688.00K | -38.41% |
| 2018-12-31 | $1.12 Million | -9.26% |
| 2017-12-31 | $1.23 Million | -58.87% |
| 2016-12-31 | $2.99 Million | +36.54% |
| 2015-12-31 | $2.19 Million | -65.42% |
| 2014-12-31 | $6.34 Million | +58.95% |
| 2013-12-31 | $3.99 Million | +82.85% |
| 2012-12-31 | $2.18 Million | +30.60% |
| 2011-12-31 | $1.67 Million | -- |
About NanoVibronix Inc
NanoVibronix, Inc., through its subsidiaries, focuses on non-invasive biological response-activating devices that target biofilm prevention, pain therapy, wound healing, and at home administration without medical professional assistance. Its product portfolio includes UroShield, an ultrasound-based product that is designed to prevent bacterial colonization and biofilm in urinary catheters, increa… Read more